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Original Research

Sepsis-Associated Acute Kidney Disease and Long-term
Kidney Outcomes
Alexander H. Flannery, Xilong Li, Natalie L. Delozier, Robert D. Toto, Orson W. Moe, Jerry Yee, and
Javier A. Neyra
Rationale & Objective: Sepsis-associated acute
kidney injury often leads to acute kidney disease
(AKD), predisposing patients to long-term
complications such as chronic kidney disease
(CKD), kidney failure with replacement therapy
(KFRT), or mortality. Risk stratiﬁcation of
patients with AKD represents an opportunity to
assist with prognostication of long-term kidney
complications.
Study Design: Single-center retrospective cohort.
Setting & Participants: 6,290 critically ill patients
admitted to the intensive care unit with severe
sepsis or septic shock. Patients were separated
into cohorts based on incident acute kidney injury
or not, and survivors identiﬁed who were alive and
free of KFRT up to 90 days.
Predictors: AKD stage (0A, 0C, or ≥1) using the
last serum creatinine concentration available by
discharge or up to 90 days postdischarge.
Outcome: Time to development of incident CKD,
progression of CKD, KFRT, or death.
Analytical Approach: Multivariable Cox proportional hazards models.

Results: Patients surviving kidney injury associated
with sepsis often fail to return to baseline kidney
function by discharge: 577/1,231 (46.9%) with
stage 0C or 1 or greater AKD. AKD stage was
signiﬁcantly associated with the composite primary
outcome. Stages 0C AKD and 1 or greater AKD
were signiﬁcantly and progressively associated
with the primary outcome when compared with
stage 0A AKD (adjusted HR [aHR], 1.74; 95% CI,
1.32-2.29, and aHR, 3.25; 95% CI, 2.52-4.20,
respectively). Additionally, stage 1 or greater AKD
conferred higher risk above stage 0C AKD (aHR,
1.87; 95% CI, 1.44-2.43). CKD incidence or progression and KFRT, more so than mortality,
occurred with greater frequency in higher stages of
AKD.
Limitations: Retrospective design, single center,
exclusion of patients with KFRT within 90 days of
discharge, potential ascertainment bias, and
inability to subclassify above AKD stage 1.
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Conclusions: Risk stratiﬁcation using recommended AKD stages at hospital discharge or
shortly thereafter associates with the development
of long-term kidney outcomes following sepsisassociated acute kidney injury.

S

epsis is the most commonly identified risk factor for
acute kidney injury (AKI), present in 26% to 50% of
all AKI cases.1-4 Compared with nonseptic AKI, sepsisassociated AKI presents with more severe AKI and
increasing risk for mortality.1 Although AKI complicates
the short-term management of patients with sepsis, it also

Editorial, p. 475
places the patient at risk for long-term complications, such
as the development of chronic kidney disease (CKD),
kidney failure with replacement therapy (KFRT), and
short- and long-term mortality.5-7 Sepsis-associated AKI
has high potential to lead to acute kidney disease (AKD), or
persistently reduced kidney function for at least 7 but less
than 90 days.8-10
Despite the prevalence of sepsis-associated AKI, longterm follow-up examination of kidney function in this
patient population remains understudied. Given the large
number of patients with sepsis-associated AKI cared for
annually and many who will develop AKD, risk stratification of these patients either at hospital discharge or shortly
thereafter will be critical to aid in prognostication, as well
as to target interventions that reduce post-AKI morbidity
Kidney Med Vol 3 | Iss 4 | July/August 2021
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and the development of kidney-11-13 and non–kidneyrelated complications such as cardiovascular disease.14-16
Before using risk stratification into AKD treatment
studies, further research is required on the link between
sepsis-associated AKD and the development of kidney
complications, including incident or progression of CKD,
development of KFRT, or death. This was the impetus for
the current study on long-term outcomes of survivors with
sepsis-associated AKI. We hypothesized that sepsisassociated AKD associates in a graded manner according
to AKD staging with long-term kidney outcomes in this
susceptible population.
METHODS
Study Design
This was a single-center retrospective cohort study of
critically ill patients admitted to the intensive care unit
(ICU) of an urban tertiary-care academic medical center.
Adult patients (aged ≥18 years) admitted to the ICU from
May 2007 to June 2012 with severe sepsis or septic
shock were identified using International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes and
previously published criteria.17 Additionally, patients
507
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PLAIN-LANGUAGE SUMMARY
Sepsis is a common cause of kidney injury in hospitalized patients that often does not resolve within days
of injury, which may place patients at risk for long-term
kidney complications. We sought to assess how the
degree of remaining kidney injury at or shortly after
hospital discharge relates to a patient’s risk for longterm kidney outcomes, including new or progressive
chronic kidney disease, dialysis, or death. Our results
showed that a commonly used classification system for
this remaining kidney injury can accurately predict
long-term kidney outcomes. These results can help
kidney professionals better identify a patient’s risk for
long-term kidney complications after sepsis and ensure
that they receive the most appropriate attention and care
following hospital discharge.

were identified as having sepsis-associated AKI based on
the serum creatinine component of the KDIGO (Kidney
Disease: Improving Global Outcomes) criteria.9 The
highest serum creatinine value during ICU admission was
used to adjudicate KDIGO AKI staging. The most recent
serum creatinine measurement within 3 months of the
index ICU admission was considered the baseline and
used to calculate estimated glomerular filtration rate
(eGFR) using the Modification of Diet in Renal Disease
(MDRD) Study equation.18 Patients surviving the ICU
admission alive and free of kidney replacement therapy
(KRT) up to 90 days following hospital discharge were
evaluated for long-term outcomes. Patients with baseline
eGFRs < 15 mL/min/1.73 m2, with KFRT before admission, or follow-up time less than 90 days after discharge
were excluded.
The study was approved by the Institutional Review
Board (#7044) with a waiver of informed consent due to
deidentification of patient information.
Study Outcomes and Deﬁnitions
Survivors of ICU admission alive and free of KRT up to 90
days following hospital discharge were evaluated for recovery of their sepsis-associated AKI, as assessed by AKD
staging, which was the independent variable of interest for
this study. If patients did not have any documented serum
creatinine measurements within 90 days following hospital discharge, their discharge serum creatinine value was
used to determine sepsis-associated AKI recovery. AKD
staging was based on the ratio of the last serum creatinine
value (hospital discharge or within 90 days from
discharge) divided by the baseline serum creatinine value
and categorized as follows based on AKD staging recommendations from the Acute Disease Quality Initiative work
group on AKD and kidney recovery: less than 1.1 stage 0A
AKD, 1.1 or greater to less than 1.5 stage 0C AKD, and 1.5
or greater stage 1 or greater AKD.8
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The primary composite outcome was CKD incidence,
progression of CKD, KFRT, or death. Incident CKD was
defined as baseline eGFR > 60 mL/min/1.73 m2, but last
eGFR < 60 mL/min/1.73 m2, and ≥25% reduction of last
eGFR from baseline eGFR.19 Progressive CKD was defined
as baseline eGFR < 60 mL/min/1.73 m2 and last
eGFR < 15 mL/min/1.73 m2 or ≥50% reduction of last
eGFR from baseline eGFR.19 The average of the last 2
eGFRs was used when available after 90 days following
hospital discharge.
Baseline demographics and comorbid conditions were
collected using ICD-9-CM codes. eGFR < 60 mL/min/
1.73 mL/min/1.73 m2 was used for defining CKD at
baseline.20 Anemia was defined as admission hematocrit < 39% for men or <36% for women. Hospital billing
codes were used to identify drug exposure, red blood cell
transfusion, and mechanical ventilation during the ICU
admission. Severity of illness was quantified using the
Sepsis-Related Organ Failure Assessment (SOFA)21 and
Acute Physiology and Chronic Health Evaluation II
(APACHE II)22 scores within the first day of ICU
admission.
Statistical Analysis
Comparisons for categorical variables were made using χ 2
test. For continuous variables, 1-way analysis of variance
was used for Gaussian and Kruskal-Wallis for non-Gaussian
distributed data. Baseline serum creatinine data were
randomly missing in the cohort and therefore multiple
imputation was conducted using SAS, version 9.4 Proc MI
(SAS Institute, Inc), fully conditional specification, with 50
imputed data sets. Variables included for imputation and
analyzed were age, sex, race, hypertension, and diabetes.
For the primary outcome of CKD incidence, progression
of CKD, KFRT, or death, a Cox proportional hazards model
was constructed using AKD status at hospital discharge (or
within 90 days from discharge if available) as the primary
independent variable. Potential confounding variables
selected for the Cox model included demographic data
(age, sex, and race); comorbid conditions (diabetes, anemia, and baseline eGFR); SOFA score as an indicator of
critical illness (SOFA was categorized by a median of 4);
and AKI characteristics (KDIGO severity classification).
Baseline eGFR was log transformed for analysis. The
selected final model was based on the significance of results (P < 0.10) through backward selection. APACHE II
was not included in the multivariable model because of
collinearity with the SOFA score. The final model was
presented with adjusted hazard ratios (aHRs) and 95% CIs.
Times to events are displayed in adjusted survival curves.
Statistical analysis was undertaken in SAS, version 9.4, and
GraphPad Prism 6.0 (GraphPad Software). P < 0.05 was
considered statistically significant. No adjustments were
made for multiple comparisons.
Several sensitivity analyses were conducted, including:
(1) modeling the composite of incident or progressive
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CKD, KFRT, and death in patients with and without CKD
at baseline, (2) using a doubling of serum creatinine
concentration23,24 rather than our primary definitions for
incident or progressive CKD, (3) by analyzing outcomes
for incident/progressive CKD and KFRT/death separately,
and (4) by modeling the composite outcome in only patients with measured baseline serum creatinine concentrations (without multiple imputation).
RESULTS
Of 6,290 patients admitted to the ICU with sepsis, 1,076
patients without AKI and 1,231 with AKI were ultimately
included in the study (Fig 1). Complete data on baseline
serum creatinine measurements were available for 1,177
of the 2,307 patients (51%), for which multiple imputation was used to estimate missing values (Table S1). Most
serum creatinine values used for AKD staging were from
the last day of hospitalization, with <10% representing a
serum creatinine measured in the 90 days following
discharge (Table S2). When the missing baseline serum
creatinine data were imputed, of the 1,231 patients with
AKI, 654 (53.1%) were classified as stage 0A AKD; 326
(26.5%), as stage 0C AKD; and 251 (20.4%), as stage 1 or
greater AKD (Table 1). The population was mostly Black
and middle-aged, with frequent comorbid conditions such
as hypertension and diabetes. The acuity of illness was
moderate as evidenced from the APACHE II and SOFA
scores, with approximately one-third of patients requiring
mechanical ventilation.
Patients were followed up for a median of 14.2 (IQR,
5.3-26.7) months. Most had at least 2 serum creatinine

6290 paents admied to
ICU with sepsis

3642 paents
with AKI

2648 paents
without AKI

2491 paents
surviving at 90
days

2191 paents
surviving at 90
days

2405 paents free
of KRT

1231 paents with
follow-up data

1076 paents with
follow-up data

Figure 1. Flow diagram of patient inclusion into the cohort. Abbreviations: AKI, acute kidney injury; ICU, intensive care unit;
KRT, kidney replacement therapy.
Kidney Med Vol 3 | Iss 4 | July/August 2021

measurements during follow-up after 90 days postdischarge for CKD adjudication (Table S3). The specific
outcomes of incident or progressive CKD, KFRT, and death
are shown across AKD stages and the no-AKI group in
Fig 2 and Table S4. Incident CKD, progressive CKD, and
need for KRT were all significantly different and progressively occurred more frequently across the different AKD
stages assessed; death was not. The adjusted survival curves
for time to development of the primary composite
outcome are shown in Figs 3 (entire cohort) and S1
(limited to patients with measured baseline serum
creatinine).
In the analysis of the primary outcome, AKD stage at
hospital discharge or within 90 days was significantly
associated with the composite of CKD incidence, progression, KFRT, or death, with worsening AKD stage
associated with a progressively greater aHR (Table 2).
Compared with stage 0A AKD, stages 0C (aHR, 1.74; 95%
CI, 1.32-2.29) and 1 or greater AKD (aHR, 3.25; 95% CI,
2.52-4.20) were both significantly associated with the
outcome of CKD incidence, progression, KFRT, or death
following 90 days postdischarge. Additionally, stage 1 or
greater AKD carried risk above that of stage 0C AKD (aHR,
1.87; 95% CI, 1.44-2.43).
In sensitivity analysis in which the cohort was stratified
by CKD status at baseline, similar findings were observed
in the overall cohort with the exception that in patients
without CKD at baseline, there was no difference in aHRs
between stage 0C and 0A AKD (Table S5). The adjusted
survival curves for patients with and without CKD are
shown in Figs S2 and S3. When doubling of serum
creatinine concentration was used in the composite
outcome rather than our primary definitions of incident or
progressive CKD, similar outcomes were observed
(Table S6). A similarly strong and graded association according to severity of AKD remained for AKD status when
the outcomes of incident/progressive CKD (Table S7) or
KRT/death (Table S8) were analyzed separately in the
overall cohort. The composite primary outcome analysis
was repeated for the cohort of patients who had measured
(nonimputed) baseline serum creatinine values (n=623)
and the progressive risks for stages 0C and 1 or greater
were confirmed when compared with stage 0A (Table S9).
The additional risk of stage 0C versus 0A AKD appeared to
be least robust in sensitivity analysis, without statistical
significance in Tables S5, S6, and S8. Otherwise, AKD
staging was confirmed to be progressively and strongly
associated with worse long-term kidney outcomes.
DISCUSSION
We evaluated long-term kidney-related outcomes of critically ill septic patients with and without AKI who survived
and were KFRT-free up to 90 days postdischarge. A large
proportion of survivors of sepsis-associated AKI, excluding
those with KFRT up to 90 days postdischarge, failed to
return to baseline kidney function as evidenced by 577/
509
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Table 1. Clinical Characteristics of Study Cohort

Demographics
Age, ya
Men
Race
Black
White
Other
Chronic conditions
Baseline Scr, mg/dLa,b
Baseline eGFR, mL/min/1.73 m2a
≥90
<90 and ≥60
<60 and ≥45
<45 and ≥30
<30 and ≥15
Diabetes
Hypertensiona
Systolic heart failure
Anemiaa
Drug exposure
Diuretica
Statin
Iodine contrasta
Aminoglycoside
Critical indicators
Oliguria 72 ha
CFB 72 h, La
LOS, d
Pressor or inotropea
Mechanical ventilation
Blood transfusion
APACHE II scorea
SOFA scorea
Dipstick albuminuria > 30 mg/dLa
AKI characteristics
AKI severity (KDIGO criteria)a
Stage 1
Stage 2
Stage 3
Hospital dialysisa
Peak Scr, mg/dLa
Discharge Scr, mg/dL a

No AKI
(n =1,076)

Stage 0A
AKD (n=654)

Stage 0C
AKD (n=326)

Stage ≥1
AKD (n=251)

63.1 ± 16.6
560 (52.0%)

63.9 ± 15.6
362 (55.4%)

64.9 ± 15.2
157 (48.2%)

59.7 ± 15.9
130 (51.8%)

489 (45.6%)
356 (33.2%)
228 (21.3%)

295 (45.6%)
229 (35.4%)
123 (19.0%)

171 (52.9%)
104 (32.2%)
48 (14.9%)

131 (52.4%)
73 (29.2%)
46 (18.4%)

1.3 ± 0.5

1.4 ± 0.5

1.3 ± 0.5

1.3 ± 0.5

155 (14.4%)
358 (33.3%)
303 (28.2%)
207 (19.2%)
53 (4.9%)
246 (22.9%)
503 (46.8%)
46 (4.3%)
861 (82.4%)

74 (11.3%)
215 (32.9%)
210 (32.1%)
121 (18.5%)
34 (5.2%)
163 (24.9%)
295 (45.1%)
29 (4.4%)
524 (81.6%)

64 (19.6%)
120 (36.8%)
72 (22.1%)
59 (18.1%)
11 (3.4%)
86 (26.4%)
143 (43.9%)
13 (4.0%)
283 (88.7%)

56 (22.3%)
78 (31.1%)
75 (29.9%)
33 (13.2%)
9 (3.6%)
51 (20.3%)
83 (33.1%)
8 (3.2%)
214 (86.3%)

(44.8%)
(33.7%)
(32.3%)
(9.7%)

282 (43.1%)
219 (33.5%)
138 (21.1%)
50 (7.7%)

167 (51.2%)
126 (38.7%)
68 (20.9%)
27 (8.3%)

127 (50.6%)
79 (31.5%)
45 (17.9%)
19 (7.6%)

425 (40.4%)
1.1 [−1.6 to 4.5]
11 [7 to 20]
257 (23.9%)
378 (35.1%)
34 (3.2%)
10 [7 to 14]
3 [1 to 5]
333 (31.0%)

273 (42.6%)
2.7 [−0.6 to 6.7]
12 [6 to 21]
212 (32.4%)
239 (36.5%)
24 (3.7%)
12 [9 to 17]
4 [2 to 7]
341 (52.1%)

145 (45.7%)
1.2 [−1.2 to 5.4]
12 [6 to 19]
94 (28.8%)
107 (32.8%)
10 (3.1%)
12 [8 to 17]
4 [2 to 7]
155 (47.6%)

130 (53.9%)
1.3 [−2.0 to 5.3]
13 [7 to 22]
68 (27.1%)
84 (33.5%)
3 (1.2%)
11 [7 to 16]
4 [2 to 7]
136 (54.2%)

—

396 (60.6%)
100 (15.3%)
158 (24.2%)
60 (9.2%)
2.2 [1.7 to 3.2]
1.1 [0.9 to 1.3]

193 (59.2%)
62 (19.0%)
71 (21.8%)
20 (6.1%)
2.2 [1.6 to 3.0]
1.4 [1.1 to 1.9]

56 (22.3%)
49 (19.5%)
146 (58.2%)
82 (32.7%)
3.6 [2.0 to 6.3]
2.6 [1.7 to 4.2]

482
363
348
104

—
1.2 [0.9 to 1.4]
1.0 [0.8 to 1.2]

Note: Values expressed as mean ± standard deviation, number (percent), or median [25th to 75th percentile].
Abbreviations: AKD, acute kidney disease; AKI, acute kidney injury; APACHE II, Acute Physiology and Chronic Health Evaluation II score; CFB, cumulative ﬂuid
balance; eGFR, estimated glomerular ﬁltration rate; iodine contrast, only if intravenous or intra-arterial; LOS, length of hospital stay; oliguria 72 h, urine output < 500 mL/d in the ﬁrst 72 hours of intensive care unit admission; Scr, serum creatinine; SOFA, Sequential Organ Failure Assessment score; KDIGO, Kidney
Disease Improving Global Outcomes.
a
P < 0.05 for comparison across all 4 groups.
b
Includes imputed missing baseline Scr value.

1,231 (46.9%) with stage 0C or 1 or greater AKD. Using
AKD staging according to the Acute Disease Quality
Initiative AKD consensus report, primarily at the time of
hospital discharge, we demonstrated progressive risk for
incident or progressive CKD, development of KFRT, or

510

death as the AKD stage increased from 0A to 0C to 1 or
greater AKD.8 Our results show that the proposed 0A, 0C,
and 1 or greater staging appropriately risk stratifies patients
at the time of discharge or within 90 days of discharge in
terms of their risk for developing long-term kidney-related

Kidney Med Vol 3 | Iss 4 | July/August 2021
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Incident/Progressive CKD

Stage 1 and higher AKD

Need for KRT
Stage 0C AKD

Death

Stage 0A AKD
No AKI
0

50

100

Percent (%)

Figure 2. Long-term kidney outcomes based on presence of acute kidney injury (AKI) and acute kidney disease (AKD) stage.
Abbreviations: CKD, chronic kidney disease; KRT, kidney replacement therapy.

complications, including incident or progressive CKD,
KFRT, or death. Importantly, this staging system associates
with CKD and dialysis-related outcomes more than death.
These data indicate that AKD status at discharge is an
important clinical parameter of long-term kidney outcomes and may serve as a measurable indictor of
impaired/maladaptive kidney repair from sepsis-associated
AKI and contributor to the development of CKD and
KFRT.8,25,26 Accordingly, the hospital stay may be an
important window of time to restore kidney function
following sepsis-associated AKI. A reduction in AKD stage
from 1 or greater to 0C, or 0C to 0A, appears to reduce the
long-term risk for kidney complications significantly.
Additionally, these data also portray a poor trajectory for
patients with sepsis-associated AKI who survive

hospitalization and are free of KRT at discharge, even those
whose serum creatinine values return to baseline by hospital discharge (stage 0A AKD). Strategies that alter this
trajectory could carry important health care implications
for the development of long-term sequalae of sepsisassociated AKI. Importantly, even patients without sepsisassociated AKI appeared to carry significant risks
following discharge. This highlights the potential importance of subclinical sepsis-associated AKI, which requires
specific injury biomarkers for detection, as well as the
importance of long-term sequelae of sepsis.27,28
Although early nephrologist follow-up after an episode
of severe AKI is associated with reduced all-cause mortality,29 the number of patients who are seen by a nephrologist within 1 year of AKI diagnosis is estimated at only

Figure 3. Adjusted survival curve for the composite outcome of incident or progressive chronic kidney disease (CKD), kidney failure
with replacement therapy (KFRT), or death. Abbreviations: AKD, acute kidney disease; AKI, acute kidney injury.
Kidney Med Vol 3 | Iss 4 | July/August 2021
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Table 2. Cox Proportional Hazards Model for the Primary
Outcome of CKD Incidence, Progression, Kidney Failure With
Replacement Therapy, or Death
Patient
Characteristics
(N = 1,231)
AKD stage at hospital
discharge or within
90 d
Stage 0C vs 0A
Stage ≥1 vs 0A
Stage ≥1 vs 0C
Age, 10-y
Man vs woman
Black vs other
Anemia
Diabetes
Log-transformed
baseline eGFR
AKI severity
AKI severity KDIGO
2-3 vs 1
AKI severity KDIGO
3D vs 1
SOFA score ≥ 4
vs <4

aHRa

95% CI

aHRb

95% CI

1.76
3.01
1.72
1.09
0.96
1.23
1.69
1.00
0.87

1.33-2.32
2.29-3.96
1.30-2.26
1.01-1.17
0.77-1.19
0.99-1.52
1.18-2.42
0.78-1.28
0.67-1.14

1.74
3.25
1.87
1.09
—
1.23
1.69
—
—

1.32-2.29
2.52-4.20
1.44-2.43
1.01-1.17
—
1.00-1.53
1.18-2.41
—
—

1.37

0.99-1.90

—

—

1.16

0.90-1.48

—

—

1.36

1.09-1.70

1.41

1.14-1.76

Abbreviations: aHR, adjusted hazard ratio; AKD, acute kidney disease; AKI,
acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular
ﬁltration rate; KDIGO, Kidney Disease: Improving Global Outcomes; SOFA,
Sequential Organ Failure Assessment.
a
Initial model.
b
Final model after backward selection.

20%.30 A recent KDIGO conference proposed that nonnephrology providers be involved in post-AKI care
depending on patient risk factors such as KDIGO stage,
recovery status, and comorbid conditions.31 The National
Institutes of Health has recently acknowledged the gap in
post-AKI care and announced the Caring for Outpatients
After Acute Kidney Injury (COPE-AKI) consortium.32
Previous literature has shown the poor long-term outcomes of patients with sepsis-associated AKI but has primarily focused on risk assessment and stratification in the
ICU. Lopes et al33 found that compared with patients
without prior AKI, patients with sepsis-associated AKI
were at greater risk for 2-year mortality. Similarly, Kim et
al34 evaluated patients at 1 year following septic
shock–associated AKI and found that KDIGO stage significantly, and progressively from stages 1-3, was associated
with all-cause mortality within 1 year. In contrast, KDIGO
stage was not associated with the development of CKD.34
This is consistent with our model development in which
KDIGO severity stage was not a significant predictor of the
composite outcome and was removed from the final
model. The implications of this finding are that KDIGO
severity classification does not capture level of kidney recovery post-AKI, which represents a surrogate of the
multimodal kidney repair pathways after AKI, and therefore the newly proposed AKD classification8 appears to be
512

a more critical factor for risk stratification of long-term
kidney-related outcomes after sepsis-associated AKI, as
shown in our study. This concept is further supported by
findings from another large cohort study demonstrating
that patient phenotypes of recovery from AKI (examples
include early sustained reversal and lack of reversal among
others) are associated with poor clinical outcomes,
including ICU mortality and mortality up to 1 year of
follow-up.35 Our findings build on the importance of recovery of kidney function in sepsis-associated AKI and to
our knowledge represent the first epidemiologic study of
long-term outcomes in sepsis-associated AKI as assessed by
the newly proposed AKD stage classification.8 Given the
high prevalence of AKD observed in survivors of sepsisassociated AKI in our study and prior work,10 the term
sepsis-associated AKD appears worthy of its own classification given the impact on survivors of sepsis. Our study
estimates of AKD may be on the higher side given that a
considerable proportion of the studied population were
Black and with underlying CKD, both clinical factors that
were previously identified to be strongly associated with
sepsis-associated AKD.10 Our sensitivity analyses suggested
that AKD classifications are more distinctly linked with
long-term kidney outcomes in patients with CKD than in
patients without CKD.
Our study has several strengths, including the large
sample size, use of consistent and recommended staging
terminology regarding AKD status, and follow-up beyond
1 year of discharge, which allow it to build on prior
literature.
Some limitations are also noteworthy to discuss,
including the retrospective single-center design and the
reliance on ICD-9-CM coding for patient identification.
Based on the design of the study, by excluding patients
who received KRT within 90 days of discharge, we may
have excluded patients on a worse recovery trajectory
from the analysis and thus our estimates, given that most
patients’ AKD status was determined at discharge, may
underestimate the risk for AKD status because these patients were excluded. The 90-day window for AKD classification was originally selected for the examination of
AKD resolution following discharge. Fewer patients than
desired had postdischarge serum creatinine values during
this 90-day window following discharge. Although we
were able to use discharge serum creatinine values in most
cases, we recognize that AKD classification at discharge
may not adequately represent a patient’s AKD stage within
a 90-day window from discharge in some cases. Due to
persistent KRT potentially influencing the postdischarge
serum creatinine to baseline serum creatinine ratio to
classify AKD stage, patients who received KRT within 90
days of hospital discharge were excluded. Due to the
retrospective nature of data acquisition, not all patients
discharged were able to contribute follow-up data and
patients may not have been able to be followed up for the
same amount of time, particularly patients with sepsisassociated AKI during the last few months of the study
Kidney Med Vol 3 | Iss 4 | July/August 2021
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period. This may have introduced ascertainment bias into
the study. Because we used only the last 2 serum creatinine measurements available during the follow-up period
to adjudicate CKD, the intensity of follow-up may have
served as a possible confounder. Additionally, the most
commonly assessed outcome of the composite end point
(CKD) was based on eGFR. The use of serum creatinine
concentrations in these equations compared with other
biomarkers such as cystatin C,36 as well as the inclusion of
race, have come under intense scrutiny in recent years,
including creation of a National Kidney Foundation/
American Society of Nephrology task force on reassessing
the inclusion of race in these equations.37 Future work in
this area will benefit from advances in eGFR consensus and
refinement. We also did not subclassify AKD higher than
stage 1 (stage ≥ 1 was used) due to the relatively smaller
number of patients in this category compared with others,
which limits our ability to make conclusions about the risk
stratification of stage 1 versus 2 versus 3 AKD.8 Finally,
although we have attempted to adjust for relevant covariates with our modeling, residual confounding may
nonetheless remain.
In conclusion, in critically ill patients surviving sepsisassociated AKI and free of KRT within 90 days of
discharge, AKD status at discharge is strongly and progressively associated with the development of long-term
kidney events, particularly CKD and KFRT. AKD stage
may therefore be an important risk stratification tool for
post-AKI care in patients surviving sepsis-associated AKI.
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What are the long-term outcomes in sepsisassociated acute kidney disease?
Retrospective study

Composite primary outcome

Single center

Kidney failure with
replacement therapy
(KFRT)

Mortality

Survivors of ICU admission
with severe sepsis or septic shock

Incident AKI
1231/2307 (53.4%)

Survivors identified
Alive & free of KFRT up to 90 days
post-discharge with follow-up sCr

14.2 months (5.3 – 26.7)
Median follow-up

Acute kidney disease (AKD)
staging
Determined and compared

Kidney function
did not return to
baseline in
577/1231 (46.9%)
AKI survivors by
discharge

CKD progression

AKD stage and aHR for composite primary outcome

Stage 0A
<1.1

Reference

AKD staging
Ratio of last sCr: baseline sCr

AKD stage was
significantly
associated with
composite primary
outcome

based on
recommendations from
the Acute Disease
Quality Initiative (ADQI)
workgroup on AKD and
kidney recovery

Conclusion: Risk stratification using recommended AKD stages at hospital

discharge or shortly thereafter associates with long-term kidney outcomes following
sepsis-associated acute kidney injury.
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Incident CKD

Stage 0C

aHR 1.74

1.1 - <1.5

1.32 – 2.29

Stage ≥1

aHR 3.25

≥1.5

2.52 – 4.20

Reference: Flannery AH, Li X, Delozier NL et al. Sepsis-associated

acute kidney disease and long-term kidney outcomes. Kidney
Medicine, 2021.
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